AWARD A CONTRACT FOR RADX TECH - CERES TO DEVELOP A WASTEWATER COVID-19 SURVEILLANCE FRAMEWORK DRIVEN BY PUBLIC HEALTH AUTHORITIES AT CITY, COUNTY AND

Ceres Nanosciences是用于提取和浓缩SARS-CoV-2的Nanotrap颗粒的开发商，已经成功地验证了这些颗粒在多个实验室和环境中的使用，以捕获和浓缩生物溶液或废水中的SARS-CoV-2，其水平目前低于现有方法的检测限。这吸引了超过15个商业合作伙伴的兴趣，例如LabCorp，他们正在领导全国为COVID-19感染提供诊断测试的努力。这些合作伙伴的累积需求是超过2，000，000/天的测试。我们目前的制造工艺无法满足这一需求，成为帮助解决国家危机的瓶颈。因此，Ceres Nanosciences正在请求RADx支持，以在我们现有的质量管理体系下快速扩大Nanotrap的生产和分销，以满足LabCorp等合作伙伴的需求，LabCorp准备利用该技术进行COVID-19感染的即时和确认测试。《欧盟协定》修正案数据收集和供应合同协议正在进行中。

Ceres Nanosciences, developer of Nanotrap particles for extracting and concentrating SARS-CoV-2, have successfully validated the use of these particles in multiple laboratories and contexts to capture and concentrate SARS-CoV-2 from biological solutions or wastewater at levels currently below the limit of detection of existing methods. This has attracted the interest of over 15 commercial partners, such as LabCorp, who are leading the national efforts to provide diagnostic tests for COVID-19 infection. The cumulative needs for these partners are tests in excess of 2,000,000/day. Our current manufacturing processes are not able to meet this demand and represent a bottleneck to helping to address the national crisis. As such, Ceres Nanosciences is requesting RADx support to rapidly scale-up Nanotrap manufacturing and distribution under our existing quality management system to meet the demand of partners, such as LabCorp, who are poised to leverage the technology for point-of-care and confirmatory testing for COVID-19 infection. EUA amendment data collection and supply contract agreements are in process.